CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 253 enrolled
Drug / intervention
A-101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03148691
NCT03148691Phase 2Completed

A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101(Hydrogen Peroxide) Topical Solution in Subjects With Seborrheic Keratosis Lesions on the Trunk, Extremities, and Face

Aclaris Therapeutics, Inc.·interventional·Posted May 11, 2017·Updated May 6, 2019

In Brief

A Phase 2 clinical trial evaluating A-101 for Seborrheic Keratosis. Completed, enrolled 253 participants across 9 sites.

Detailed Summary

The primary objective of this study is to evaluate the safety and effectiveness of 2 concentrations of A-101 compared to Vehicle for the treatment of 4 seborrheic keratosis (SK) Target Lesions on the trunk, extremities and face.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 11, 2017
Enrollment StartMay 17, 2017
Primary CompletionFeb 28, 2018
Study CompletionApr 3, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.1 years ago

Interventions

A-101drug

Topical Solution